Submission seeks to extend the Ameluz� label beyond the face and scalp to treatment fields of up to approximately 240 cm� on the rest of the body, with an adjusted illumination protocol ... .
Biofrontera Announces FDA Approval of Ameluz® Red LightPDT for the Treatment of SuperficialBasal Cell Carcinoma... This label expansion also furthers Biofrontera's strategy of broadening the clinical utility of its Red-Light PDT platform.